Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Venous Thromboembolism 16 Venous Thrombosis 12 Pulmonary Embolism 11 Neoplasms 10 Thrombosis 4 Thromboembolism 4 Pancreatic Neoplasms 4 Lung Neoplasms 4 Multiple Myeloma 3 Neoplasm Metastasis 2 Lymphoma 2 Hemorrhage 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Thrombophilia 1 Thrombocytopenia 1 Thrombocythemia, Essential 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Ovarian Neoplasms 1 Obesity 1 Neoplasms, Plasma Cell 1

Interventions

Paclitaxel 328 Carboplatin 323 Bevacizumab 171 Gemcitabine 106 liposomal doxorubicin 104 pembrolizumab 101 Cyclophosphamide 96 Topotecan 94 olaparib 92 Cisplatin 92 niraparib 69 Docetaxel 57 Taxes 52 Doxorubicin 51 Drug Therapy 45 fludarabine 40 Filgrastim 39 Nivolumab 37 Magnetic Resonance Spectroscopy 34 Surveys and Questionnaires 33 Specimen Handling 33 Etoposide 32 Hyperthermic Intraperitoneal Chemotherapy 31 Blood Specimen Collection 29 Immunoglobulin G 27 Disulfides 27 Peripheral Blood Stem Cell Transplantation 26 Cytoreduction Surgical Procedures 25 Albumin-Bound Paclitaxel 25 durvalumab 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × Dalteparin × Clear all

NCT00239980 2010-02-03

FOCUS

Ontario Clinical Oncology Group (OCOG)

Phase 2 Completed

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡